Apixaban to prevent early liver cirrhosis complications
Treatments studied
Part of Digestive system clinical trials.
This trial tests if the blood thinner apixaban can prevent liver cirrhosis from getting worse in people with alcohol-related liver disease. It may help reduce the risk of serious complications like fluid buildup or bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cirrhosis from alcohol, with or without other metabolic factors.
- Your cirrhosis is confirmed by a biopsy, imaging like ultrasound or MRI, or special tests like FibroScan.
- You have mild cirrhosis (Childs A) or had complications before but are now stable.
- You have no or only mild confusion from liver disease (controlled with medication).
- You are 18 or older.
- You have signs of high blood pressure in the liver portal vein, such as enlarged veins, mild fluid around the liver, or a FibroScan score over 20.
- Your platelet count is at least 50,000 and you are not already on blood thinners or certain heart medications.
- You have good kidney function (eGFR over 30) and no recent bleeding in the esophagus or stomach.
- You do not have liver cancer or another cancer that would shorten your life.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This Phase 2 study tests a blood-thinner called a DOAC in people with previously diagnosed mild or moderate liver cirrhosis (Child A or B). It may help doctors understand whether the medicine is safe and effective in this group.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
This trial tests whether taking low-dose aspirin can help prevent liver cancer in people with cirrhosis (scarring of the liver). Cirrhosis makes the liver more likely to develop cancer, and aspirin might reduce that risk.
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.